Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
98 hedge funds and large institutions have $107M invested in Y-mAbs Therapeutics in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 31 increasing their positions, 36 reducing their positions, and 6 closing their positions.
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
3% more funds holding
Funds holding: 95 → 98 (+3)
0.42% more ownership
Funds ownership: 44.65% → 45.07% (+0.42%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
14% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 36
19% less capital invested
Capital invested by funds: $132M → $107M (-$25.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$2.23M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$915K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$653K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$540K |
| 5 |
D.E. Shaw & Co
New York
|
+$430K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.77M |
| 2 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$594K |
| 3 |
Two Sigma Investments
New York
|
-$534K |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$522K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$387K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EGM
101
Engineers Gate Manager
New York
| – | -$95.7K | -14,100 | Closed |
|
|
GCM
102
Graham Capital Management
Rowayton,
Connecticut
| – | -$68.4K | -10,075 | Closed |
|
|
QT
103
Quantbot Technologies
New York
| – | -$6.11K | -900 | Closed |
|
104
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$379 | +65 | New |
|
YMAB Hedge Fund Activity: Q3 2023 in Review
98 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q3 2023, worth a combined $107M — down 19% from $132M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new YMAB positions and 6 closed out — a net gain of 3 holders — while 31 added to existing stakes and 36 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $2.23M. The largest seller was Point72 Asset Management, cutting an estimated $1.77M.
- 98 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q3 2023, up from 95 in Q2 2023.
- Funds reported $107M of Y-mAbs Therapeutics stock for Q3 2023, down 19% quarter-over-quarter.
- 9 funds opened new Y-mAbs Therapeutics positions in Q3 2023 and 6 closed out, a net change of +3 holders.
- The largest Y-mAbs Therapeutics buyer in Q3 2023 was Citadel Advisors, an estimated $2.23M added.
- The largest Y-mAbs Therapeutics seller in Q3 2023 was Point72 Asset Management, an estimated $1.77M sold.
Based on aggregated 13F filings for Q3 2023.